Abstract
The study aimed to examine whether L-carnitine and its derivatives, acetyl-L-carnitine and propionyl-L-carnitine, were equally effective and able to improve postischemic cardiac function, reduce the incidence of reperfusion-induced ventricular fibrillation, infarct size, and apoptotic cell death in ischemic/reperfused isolated rat hearts. There are several studies indicating that L-carnitine, a naturally occurring amino acid and an essential cofactor, can improve mechanical function and substrate metabolism not only in hypertrophied or failing myocardium but also in ischemic/reperfused hearts. The effects of L-carnitine, acetyl-L-carnitine, and propionyl-L-carnitine, on the recovery of heart function, incidence of reperfusion-induced ventricular fibrillation (VF), infarct size, and apoptotic cell death after 30 min ischemia followed by 120 min reperfusion were studied in isolated working rat hearts. Hearts were perfused with various concentrations of L-carnitine (0.5 and 5 mM), acetyl-L-carnitine (0.5 and 5 mM), and propionyl-L-carnitine (0.05, 0.5, and 5 mM), respectively, for 10 min before the induction of ischemia. Postischemic recovery of CF, AF, and LVDP was significantly improved in all groups perfused with 5 mM of L-carnitine, acetyl-L-carnitine, and propionyl-L-carnitine. Significant postischemic ventricular recovery was noticed in the hearts perfused with 0.5 mM of propionyl-L-carnitine, but not with the same concentration of L-carnitine or L-acetyl carnitine. The incidence of reperfusion VF was reduced from its control value of 90 to 10% (p < 0.05) in hearts perfused with 5 mM of propionyl-L-carnitine only. Other doses of various carnitines failed to reduce the incidence of VF. The protection in CF, AF, LVDP, and VF reflected in a reduction in infarct size and apoptotic cell death in hearts treated with various concentrations of carnitine derivatives. The difference between effectiveness of various carnitines on the recovery of postischemic myocardium may be explained by different membrane permeability properties of carnitine and its derivatives.
Similar content being viewed by others
References
Anand I, Chandrashekhan Y, De Giuli F, Pasini E, Mazzoletti A, Confortini R, Ferrari R: Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 12: 291-299, 1998
El-Banani H, Bernard M, Cozzone P, James F, Feuvray D: Ionic and metabolic imbalance as potential factors of ischemia/reperfusion injury. Am J Cardiol 82: K25-K29, 1998
Lopaschuk G: Regulation of carbohydrate metabolism in ischemia and reperfusion. Am Heart J 139: S115-S119, 2000
Bremer J: Carnitine-metabolism and functions. Physiol Rev 63: 1420-1480, 1983
Saddik M, Lopaschuk G: Myocardial triglyceride turnover and contribution to energy substrate utilization in isolated working rat hearts. J Biol Chem 266: 8162-8170, 1991
Saddik M, Gamble J, Witters LA, Lopaschuk G: Acetyl-CoA carboxylase regulation of fatty acid oxidation in the heart. J Biol Chem 268: 25836-25845, 1993
Alhomida AS: Study of the effects of theophylline-related changes in total, free, short-chain acyl and long-chain acyl carnitine concentrations in rat heart. Toxicology 121: 205-213, 1997
Sethi R, Dhalla KS, Ganguly PK, Ferrari R, Dhalla NS: Beneficial effects of propionyl-L-carnitine on sarcolemmal changes in congestive heart failure due to myocardial infarction. Cardiovasc Res 42: 607-615, 1999
Kamiya H, Okumura K, Ito M, Matsui H, Saburi Y, Hayashi K, Hayakawa T: Antioxidant changes in the hypertrophied heart due to energy metabolic disorder. Basic Res Cardiol 96: 431-438, 2001
Ferrari R, Pasini E, Condorelli E, Boraso A, Lisciani R, Marzo A, Visiou O: Effects of propionyl-L-carnitine on mechanical function of isolated and perfused hearts. Cardiovasc Drugs Ther 5: 109-115, 1991
Bartels L: Effects of L-propionyl-carnitine on ischemia-induced myocardial dysfunction in man with angina pectoris. Am J Cardiol 74: 125-130, 1994
Tosaki A, Hellegouarch A: Adenosine triphosphate-sensitive potassium channel blocking agent ameliorates, but the opening agent aggravates, ischemia/reperfusion-induced injury. Heart function studies in nonfibrillating isolated hearts. J Am Coll Cardiol 23: 487-496, 1994
Schultz JEJ, Yao Z, Cavero I, Gross GJ: Glibenclamide-induced blockade of ischemic preconditioning is time dependent in intact rat heart. Am J Physiol 272: H2607-H2615, 1997
Hattori R, Otani H, Maulik N, Das DK: Pharmacological preconditioning with resveratrol: Role of nitric oxide. Am J Physiol 282: H1988-H1995, 2002
Maulik N, Kagan VE, Tyurin VA, Das DK: Redistribution of phosphatidylethanolamine and phosphatidylserine precedes reperfusion-induced apoptosis. Am J Physiol 274: H242-H248, 1998
Broderick TL, Quinney HA, Lopaschuk GD: Carnitine stimulation of glucose oxidation in the fatty acid perfused isolated working rat heart. J Biol Chem 267: 3758-3762, 1992
Arsenian MA: Carnitine and its derivatives in cardiovascular disease. Prog Cardiovasc Dis 40: 265-286, 1997
Lopaschuk G: Carnitine and myocardial glucose metabolism. In: C. De Diamone, G. Famkularo (eds). Carnitine Today. RG Landes, Austin, TX, 1997, pp 71-93
Freitz IB: Action of carnitine on long chain fatty acid oxidation by liver. Am J Physiol 197: 297-304, 1959
Neely JR, Morgan HE: Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Ann Rev Physiol 36: 413-454, 1974
Pande SV, Blanchaer MC: Reversible inhibition of mitochondrial adenosine diphosphate phosphorylation by long chain acyl coenzyme A esters. J Biol Chem 246: 402-411, 1971
Corr PB, Creer MH, Yamada KA, Saffitz JE, Sobel BE: Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. J Clin Invest 83: 927-936, 1989
Yamada KA, Kanter EM, Newatia A: Long-chain acylcarnitine induces Ca2+ efflux from the sarcoplasmic reticulum. J Cardiovasc Pharmacol 36: 14-21, 2000
Wu J, McHowat J, Saffitz JE, Yamada KA, Corr PB: Inhibiton of gap junctional conductance by long chain acylcarnitines and their preferential accumulation in junctional sarcolemma during hypoxia. Circ Res 72: 879-889, 1993
Clarke B, Wyatt KM, May GR, McCormack JG: On the roles of long-chain acyl carnitine accumulation and impaired glucose utilization in ischemic contracture development and tissue damage in the guinea-pig heart. J Mol Cell Cardiol 28: 171-181, 1996
Wu J, Corr PB: Palmitoylcarnitine increases [Na+]i and initiates transient inward current in adult ventricular myocytes. Am J Physiol 268: H2405-H2417, 1995
Yamada KA, McHowatt J, Yan GX, Donahue K, Peirick J, Kleber AG, Corr PB: Cellular uncoupling induced by accumulation of long-chain acylcarnitine during ischemia. Circ Res 74: 83-95, 1994
Haigney MCP, Miyata H, Lakatta EG, Stern MD: Dependence of hypoxic cellular calcium loading on Na+-Ca2+ exchange. Circ Res 71: 547-557, 1992
Haigney MCP, Lakatta EG, Stern MD, Silverman HS: Sodium channel blockade reduces hypoxic sodium loading and sodium dependent calcium loading. Circulation 90: 391-399, 1994
Mutomba MC, Yuan H, Konyavko M, Adachi S, Yokoyama CB, Esser V, McGarry JD, Babior BM, Gottlieb RA: Regulation of activity of caspases by L-carnitine and palmitoylcarnitine. FEBS Lett 478: 19-25, 2000
Kong JY, Rabkin SW: Palmitate-induced cardiac apoptosis is mediated through CPT-1 but not influenced by glucose and insulin. Am J Physiol 282: H717-H725, 2002
Verani MS, Jeroudi MO, Mahmarian JJ, Boyee TM, Borges-Neto S, Patel B, Bolli R: Quantification of myocardial infarction during coronary occlusion and myocardial salvage after reperfusion using cardiac imaging with technetium-99m hexakis 2-methoxyisobutyl isonitrile. J Am Coll Cardiol 12: 1573-1581, 1988
Yamashita N, Baxter GF, Yellon DM: Exercise directly enhances myocardial tolerance to ischemia-reperfusion injury in the rat through a protein kinase C mediated mechanism. Heart 85: 331-336, 2001
Liao Z, Brar BK, Cai Q, Stephanov A, O'Leary RM, Pennica D, Yellon DM, Latchman DS: Cardiotrophin-1 (CT-1) can protect the adult heart from injury when added both prior to ischemia and at reperfusion. Cardiovasc Res 53: 902-910, 2002
Maulik N, Sato M, Price BD, Das DK: An essential role of NF-κB in tyrosine kinase signaling of p38 MAP kinase regulation of myocardial adaptation to ischemia. FEBS Lett 429: 365-369, 1998
Yamashita K, Kajstura J, Discher DJ, Wasserlauf BJ, Bishopric NH, Anversa P, Webster KA: Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor 1. Circ Res 88: 609-614, 2001
Leri A, Liu Y, Claudio PP, Kajstura J, Wang X, Wang S, Kang P, Malhotra A, Anversa P: Insulin-like growth factor-1 induces Mdm2 and down-regulates p53, attenuating the myocytes renin-angiotensin system and stretch-mediated apoptosis. Am J Pathol 154: 567-580, 1999
Jonassen AK, Brar BK, Mjos OD, Sack MN, Latchman DS, Yellon DM: Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. J Mol Cell Cardiol 32: 757-764, 2000
Schaffer SW, Ballard-Croft C, Solodushko V: Cardioprotective effect of chronic hyperglycemia: Effect on hypoxia-induced apoptosis and necrosis. Am J Physiol 278: H1948-H1954, 2000
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cui, J., Das, D.K., Bertelli, A. et al. Effects of L-carnitine and its derivatives on postischemic cardiac function, ventricular fibrillation and necrotic and apoptotic cardiomyocyte death in isolated rat hearts. Mol Cell Biochem 254, 227–234 (2003). https://doi.org/10.1023/A:1027368018064
Issue Date:
DOI: https://doi.org/10.1023/A:1027368018064